US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Eikon Therapeutics (EIKN): Merck Alumni Lead Late-Stage Immuno-Oncology IPO Candidate

Eikon Therapeutics (EIKN): Late-Stage Immuno-Oncology IPO Prices with Strength, Flops on Debut

Eikon Therapeutics (EIKN): Six Months Later: Priced for Perfection, Punished by Reality

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

IPOs and Secondary Offerings

Equity Capital Markets

Eikon Therapeutics / Equity Capital Markets

<ul>
<li>Eikon Therapeutics (EIKN) set IPO terms for 17.6 million shares at $16–$18, targeting a market capitalization of up to $908 million valuation </li>
<li>Lead candidate EIK1001 is in a global Phase 2/3 registrational trial for advanced melanoma, with additional lung cancer and oncology programs underway.</li>
<li>The IPO values Eikon below its 2025 Series D valuation above $1.5 billion, offering a discounted entry amid improving late-stage biotech sentiment.</li>
</ul>


Eikon Therapeutics (EIKN) set IPO terms for 17.6 million shares at $16–$18, targeting a market capitalization of up to $908 million valuation 
Lead candidate EIK1001 is in a global Phase 2/3 registrational trial for advanced melanoma, with additional lung cancer and oncology programs underway.
The IPO values Eikon below its 2025 Series D valuation above $1.5 billion, offering a discounted entry amid improving late-stage biotech sentiment.


Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms